Multiple sclerosis progression: time for a new mechanism-driven framework

T Kuhlmann, M Moccia, T Coetzee, JA Cohen… - The Lancet …, 2023 - thelancet.com
Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—
relapsing-remitting, secondary progressive, and primary progressive—for patient care …

Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting

M Charabati, MA Wheeler, HL Weiner, FJ Quintana - Cell, 2023 - cell.com
Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central
nervous system afflicting nearly three million individuals worldwide. Neuroimmune …

How patients with multiple sclerosis acquire disability

FD Lublin, DA Häring, H Ganjgahi, A Ocampo… - Brain, 2022 - academic.oup.com
Patients with multiple sclerosis acquire disability either through relapse-associated
worsening (RAW) or progression independent of relapse activity (PIRA). This study …

Treatment of multiple sclerosis: a review

SL Hauser, BAC Cree - The American journal of medicine, 2020 - Elsevier
Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of
the central nervous system, and the leading cause of nontraumatic neurological disability in …

Acute clinical events identified as relapses with stable magnetic resonance imaging in multiple sclerosis

A Gavoille, F Rollot, R Casey, A Kerbrat… - JAMA …, 2024 - jamanetwork.com
Importance Understanding the association between clinically defined relapses and
radiological activity in multiple sclerosis (MS) is essential for patient treatment and …

Secondary progressive multiple sclerosis: new insights

BAC Cree, DL Arnold, J Chataway, T Chitnis, RJ Fox… - Neurology, 2021 - AAN Enterprises
In most cases, multiple sclerosis (MS) begins with a relapsing-remitting course followed by
insidious disability worsening that is independent from clinically apparent relapses and is …

The potential of serum neurofilament as biomarker for multiple sclerosis

S Bittner, J Oh, EK Havrdová, M Tintoré, F Zipp - Brain, 2021 - academic.oup.com
Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal
damage as well as its quantification is a critical step for patients. Blood-based serum …

Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis

C Tur, P Carbonell-Mirabent, Á Cobo-Calvo… - JAMA …, 2023 - jamanetwork.com
Importance Progression independent of relapse activity (PIRA) is the main event responsible
for irreversible disability accumulation in relapsing multiple sclerosis (MS). Objective To …

Advances in neurodegenerative diseases

J Van Schependom, M D'haeseleer - Journal of clinical medicine, 2023 - mdpi.com
Neurological disorders are the leading cause of physical and cognitive disability across the
globe, currently affecting approximately 15% of the worldwide population [1]. Absolute …

Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis

A Cagol, S Schaedelin, M Barakovic, P Benkert… - JAMA …, 2022 - jamanetwork.com
Importance The mechanisms driving neurodegeneration and brain atrophy in relapsing
multiple sclerosis (RMS) are not completely understood. Objective To determine whether …